Literature DB >> 11965274

Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial.

W S Atkin, C F Cook, J Cuzick, R Edwards, J M A Northover, J Wardle.   

Abstract

BACKGROUND: This randomised controlled trial is examining the hypothesis that a single flexible sigmoidoscopy screening offered at around age 60 years can lower the incidence and mortality of colorectal cancer. We report here on acceptability, safety, feasibility, and yield.
METHODS: Men and women aged 55-64 years, in 14 UK centres, who responded to a mailed questionnaire that they would attend for flexible sigmoidoscopy screening if invited, were randomly assigned screening or control (ratio one to two). The control group was not contacted. Small polyps were removed during screening, and colonoscopy was undertaken if high-risk polyps (three or more adenomas, size 1 cm or greater, villous, severely dysplastic, or malignant) were found.
FINDINGS: Of 354,262 people asked about their interest in having flexible sigmoidoscopy screening, 194,726 (55%) responded positively, and 170,432 eligible individuals were randomised. Attendance among those assigned screening was 71% (40,674 of 57,254). 2131 (5%) were classified as high-risk and referred for colonoscopy; 38,525 with no polyps or only low-risk polyps detected were discharged. Distal adenomas were detected in 4931 (12.1%) and distal cancer in 131 (0.3%). Proximal adenomas were detected in 386 (18.8% of those undergoing colonoscopy) and proximal cancer in nine cases (0.4%). 62% of cancers were Dukes' stage A or locally excised. There was one perforation after flexible sigmoidoscopy and four after colonoscopy. An average of 48 people were screened, and two or three colonoscopy referrals generated, per centre each week. Interpretation Our flexible sigmoidoscopy screening regimen is acceptable, feasible, and safe. The prevalence of neoplasia is high, and colonoscopy referral rates of 5% are acceptable.

Entities:  

Mesh:

Year:  2002        PMID: 11965274     DOI: 10.1016/S0140-6736(02)08268-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  104 in total

1.  Are proximal colorectal cancers always associated with distal adenomas?

Authors:  A J M Watson
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

Review 2.  Protagonist: population based endoscopic screening for colorectal cancer.

Authors:  W S Atkin; J M A Northover
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

Review 3.  Antagonist: population based endoscopic screening for colorectal cancer.

Authors:  D A L Macafee; J H Scholefield
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

Review 4.  Recent developments in gastroenterology.

Authors:  Paul Moayyedi; Alex Ford
Journal:  BMJ       Date:  2002-12-14

5.  [Colorectal cancer in Germany. Means for prevention and early detection: implications for laiety and physicians].

Authors:  A Eickhoff; C Maar; B Birkner; J F Riemann
Journal:  Internist (Berl)       Date:  2003-03       Impact factor: 0.743

6.  Colorectal cancer screening in Canada: why not consider nurse endoscopists?

Authors:  Linda Rabeneck; Lawrence F Paszat
Journal:  CMAJ       Date:  2003-08-05       Impact factor: 8.262

7.  Probing the occult: testing for blood in the stools.

Authors:  Denis M McCarthy
Journal:  Dig Dis Sci       Date:  2010-06       Impact factor: 3.199

8.  Flexible sigmoidoscopy--valuable in colorectal cancer.

Authors:  Eliza A Hawkes; David Cunningham
Journal:  Nat Rev Clin Oncol       Date:  2010-09       Impact factor: 66.675

9.  Willingness-to-pay and demand curves: a comparison of results obtained using different elicitation formats.

Authors:  David K Whynes; Emma J Frew; Jane L Wolstenholme
Journal:  Int J Health Care Finance Econ       Date:  2005-12

10.  Colorectal cancer screening in Europe.

Authors:  Miroslav Zavoral; Stepan Suchanek; Filip Zavada; Ladislav Dusek; Jan Muzik; Bohumil Seifert; Premysl Fric
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.